Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Experiments With Partnering Models For a Phase IIa Ulcerative Colitis Compound

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas out-licensed a melanocortin receptor agonist to a virtual company backed by Astellas' corporate venture arm.

You may also be interested in...



Start-Up Quarterly Statistics, Q2 2012

In the second quarter of 2012, start-up companies raised a total of $556 million across all industries. Most of that financing – $439.8 million – went to the biopharma sector. Cancer was the most prevalent therapeutic area for alliances. There were just four start-up acquisitions – two each in the biopharma and medical device industries.

For Some VCs And Execs, Familiarity Breeds More Start-Ups

As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.

For Some VCs And Execs, Familiarity Breeds More Start-Ups

As biotech funding dwindles, investors are looking for ways to repurpose the technology, platforms, and products – and to revisit lucrative relationships – from previous investments. Two recent company launches are perfect examples.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS074081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel